Keyphrases
Psoriasis
100%
During Pregnancy
100%
TNF Inhibitors
100%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
Uncertain Risk
14%
Golimumab
14%
Immunoglobulin G Antibodies
14%
Medical Subject Headings (MeSH)
14%
Second Trimester
14%
PubMed
14%
Infliximab
14%
Preterm Birth
14%
Congenital Malformations
14%
Adverse Pregnancy Outcomes
14%
Confounding by Indication
14%
Chronic Inflammatory Diseases
14%
Systemic Treatment
14%
Inhibitor Treatment
14%
Immune-mediated Inflammatory Diseases
14%
Biological Agents
14%
Immune System
14%
Adverse Outcomes
14%
Treatment Options
14%
Moderate-to-severe Psoriasis
14%
Placenta
14%
Adalimumab
14%
Intracellular Infection
14%
Medicine and Dentistry
Psoriasis
100%
TNF Inhibitor
100%
Inflammatory Disorder
25%
Biological Product
12%
Adalimumab
12%
Premature Labor
12%
Adverse Outcome
12%
Congenital Malformation
12%
Placenta
12%
Hypersensitivity
12%
Golimumab
12%
Immunity
12%
Immune System
12%
Systemic Therapy
12%
Infection
12%
Second Trimester Pregnancy
12%
Infliximab
12%
Immunoglobulin G Antibody
12%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Tumor Necrosis Factor Inhibitor
100%
Inflammatory Disease
25%
Golimumab
12%
Biological Product
12%
Premature Labor
12%
Infection
12%
Congenital Malformation
12%
Systemic Treatment
12%
Adverse Outcome
12%
Adalimumab
12%
Immunoglobulin G Antibody
12%
Infliximab
12%
Erethism
12%
Immunology and Microbiology
TNF Inhibitor
100%
Infliximab
12%
Hypersensitivity
12%
Immunoglobulin G Antibody
12%
Immune System
12%
Adalimumab
12%
Second Trimester Pregnancy
12%
Medline
12%
Medical Subject Heading
12%
Placenta
12%
Biological Product
12%
Inflammatory Disorder
12%
Golimumab
12%
Immune-Mediated Inflammatory Diseases
12%